Figure 1

EVT CM enhanced HESC decidualization via profilin 1 (PFN1). (a) HESCs (n = 4) were treated with E for 14 days and CM treatments (Hek293, HTR8[/SVneo], EVT) included from day 7. PRL secretion was measured on day 14. PRL secretion was significantly elevated by factors in EVT CM compared to media alone or cell line control CMs. (b) HESCs (n = 4) were treated with E+MPA for 14 days with CM treatments (Hek293, HTR8, EVT) included from day 7. PRL secretion was measured on day 14. PRL secretion was elevated in HESC treated with EVT CM compared to Hek293 control CM but not significantly changed compared to media alone or HTR8/SVneo CM. (c) Only EVT CM contained progesterone (n = 5). (d) PRL secretion by HESC was significantly higher when treated with EVT CM compared to a range (0–300 nmol/L) of MPA concentrations (n = 3/group). (e–k) HESCs were decidualized with E+MPA for 12 days before being subjected to functional assays with CM or PFN1 treatments. (e–g) Decidualized HESC adhesion (e, n = 3), proliferation (f, n = 4) and migration (g, n = 6) were significantly enhanced by treatment with EVT CM. (h) PFN1 treatment during decidualization (days 7–14 of E+MPA treatment) significantly increased HESC PRL secretion on day 14 (h, n = 4). i. PFN1 treatment significantly enhanced proliferation of decidualized HESC (n = 3). (j,k) PFN1 treatment had no effect on decidualized HESC adhesion (j; n = 3) or migration (k; n = 4). Data are mean ± SEM, *p < 0.05, significant difference from control; ^p < 0.05 significant difference between treatments labelled with ^. a,b,d: Friedman test; d,e,f,g,h: paired t-test; i, j,k: repeated measures one-way ANOVA.